ReviewJournal of pharmaceutical policy and practice2017
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
Review in Journal of pharmaceutical policy and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- TRIPS flexibilities help change policy and practice to increase access to medicines: evidence from 2001 to 2024.BMJ global health · 2026Article
- From proposal to compromise: the TRIPS waiver debate and the crisis of WTO decision-making.Globalization and health · 2025Review
- Perspectives and Update on the Global Shortage of Verteporfin (VisudyneOphthalmology and therapy · 2024Article
- Shaping the future of global access to safe, effective, appropriate and quality health products.BMJ global health · 2024Article
- Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care.Acta ophthalmologica · 2022Article
- Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities.American journal of public health · 2022Article
- 3D Printing, Intellectual Property Rights and Medical Emergencies: In Search of New Flexibilities.IIC; international review of industrial property and copyright law · 2022Article
- Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too.BMJ global health · 2021Article
- Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis.Globalization and health · 2019Article
- Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?Global health action · 2019Article
- Strategic procurement and international collaboration to improve access to medicines.Bulletin of the World Health Organization · 2017Article
- Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a half ago the use of flexibilities contained in the World Trade Organization Agreement on Trade Related Aspects of Intellectual Property Rights, in particular compulsory licensing, was seen as a mechanism to respond to high-price medicines for the treatment of HIV/AIDS in low- and middle-income countries. Today a number of upper-income European Union (EU) Member States are contemplating the use of compulsory licensing in their efforts to reduce expenditure on pharmaceutical products. EU regulation of clinical test data protection and the granting of market exclusivity interfere with the effective use of compulsory licensing by EU Member States and can even prevent access to off-patent medicines because they prohibit registration of generic equivalents. EU pharmaceutical legislation should be amended to allow waivers to data and market exclusivity in cases of public health need and when a compulsory or government use license has been issued. Such an amendment can be modelled after existing waivers in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.